Upcoming events on VERTEX PHARMACEUTICALS |
|
04/29/21 | | Q1 2021 Earnings Release (Projected) |
07/28/21 | | Interim 2021 Earnings Release (Projected) |
10/27/21 | | Q3 2021 Earnings Release (Projected) |
02/02/22 | | FY 2021 Earnings Release (Projected) |
|
Past events on VERTEX PHARMACEUTICALS |
|
02/01/21 | 04:30pm | | FY 2020 Earnings Call |
02/01/21 | 04:01pm | | FY 2020 Earnings Release |
01/11/21 | 09:10am | | JP Morgan Healthcare Conference |
12/09/20 | 08:00am | | CTX001™ Phase 1/2 Study Results Call |
|
Upcoming sector events for VERTEX PHARMACEUTICALS |
|
|
|
Past sector events for VERTEX PHARMACEUTICALS |
|
|
|
Annual results | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 (e) |
Sales M $ |
Released Forecast Spread | 1 702 1 696 0,38% | 2 489 2 431 2,4% | 3 048 2 992 1,9% | 4 163 3 759 11% | 6 206 6 159 0,76% | 6 947
|
Operating income (EBITDA) M $ |
Released Forecast Spread | 71,3 58,7 22% | 185 119 56% | 1 184 1 123 5,4% | 1 893 1 770 6,9% | 3 601 3 649 -1,3% | 4 190
|
Operating profit (EBIT) M $ |
Released Forecast Spread | 288 278 3,8% | 564 538 4,9% | 1 112 1 052 5,7% | 1 786 1 609 11% | 3 491 3 471 0,58% | 3 846
|
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | -67,4 -91,9 27% | -15,7 -70,5 78% | 600 771 -22% | 1 395 964 45% | 3 117 2 891 7,8% | 3 152
|
Net income M $ |
Released Forecast Spread | -112 -135 17% | 263 237 11% | 2 097 740 183% | 1 177 796 48% | 2 712 2 608 4,0% | 2 558
|
EPS $ |
Released Forecast Spread | -0,46 -0,55 17% | 1,04 0,90 15% | 8,09 2,84 185% | 4,51 3,08 46% | 10,3 9,87 4,2% | 9,86
| Announcement Date | 01/25/2017 | 01/31/2018 | 02/05/2019 | 01/30/2020 | 02/01/2021 | |
|
|
Quarterly results | 2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 | 2021 Q1 (e) | 2021 Q2 (e) | 2021 Q3 (e) | 2021 Q4 (e) | 2022 Q1 (e) |
Sales M $ |
Released Forecast Spread | 785 782 0,33% | 870 818 6,3% | 858 853 0,64% | 941 885 6,4% | 950 948 0,15% | 1 413 1 013 40% | 1 515 1 287 18% | 1 524 1 393 9,4% | 1 538 1 480 3,9% | 1 628 1 585 2,7% | 1 658
| 1 705
| 1 751
| 1 801
| 1 882
|
Operating income (EBITDA) M $ |
Released Forecast Spread | 314 297 5,6% | 367 310 18% |
|
|
| 619 483 28% | 747 759 -1,6% | 901 875 2,9% | 881 890 -1,1% | 916 1 001 -8,5% | 1 030
| 1 060
| 1 125
| 1 135
|
|
Operating profit (EBIT) M $ |
Released Forecast Spread | 295 285 3,6% | 348 312 12% | 377 335 12% | 413 357 16% | 403 400 0,71% | 593 429 38% | 877 628 40% | 874 725 21% | 854 797 7,2% | 887 872 1,7% | 920
| 942
| 958
| 991
| 1 002
|
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 137 187 -27% | 32,5 205 -84% | 320 228 40% | 327 249 31% | 70,7 199 -65% | 677 237 185% | 658 531 24% | 825 569 45% | 746 658 13% | 889 704 26% | 760
| 784
| 799
| 825
| 861
|
Net income M $ |
Released Forecast Spread | 129 187 -31% | 1 551 201 671% | 269 187 44% | 267 199 34% | 57,5 189 -70% | 583 189 208% | 603 408 48% | 837 433 93% | 667 523 28% | 604 577 4,8% | 620
| 637
| 649
| 656
| 701
|
EPS $ |
Released Forecast Spread | 0,50 0,71 -29% | 5,97 0,74 704% | 1,03 0,73 41% | 1,03 0,76 35% | 0,22 0,73 -70% | 2,23 0,76 194% | 2,29 1,60 43% | 3,18 1,66 91% | 2,53 1,98 28% | 2,30 2,13 8,2% | 2,28
| 2,35
| 2,39
| 2,45
| 2,62
| Announcement Date | 10/24/2018 | 02/05/2019 | 04/30/2019 | 07/31/2019 | 10/30/2019 | 01/30/2020 | 04/29/2020 | 07/30/2020 | 10/29/2020 | 02/01/2021 | | | | | |
|
Financial data source © 2021 S&P Global Market Intelligence
|
|
© 2021 Factset
|
|
|
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|